Biomanufacturing APAC

What factors influence tissue healing and adhesion prevention during the postoperative recovery window today?

Long-term surgical recovery is often defined less by the procedure itself than by what happens during the critical healing window following surgery, when tissues heal and postoperative adhesions can form. It is within this window that BioRegen Biomedical (Changzhou) Co., Ltd operates, developing proprietary hyaluronic acid-based biomaterials designed to prevent adhesions and promote tissue repair.

BioRegen’s hallmark is its internationally patented Self-Crosslinking of Hyaluronic Acid technology, designed to address a persistent clinical challenge. Conventional anti-adhesion barriers often degrade too quickly or exhibit high fluidity, migrating from the application site before the critical healing phase is complete.

The solution creates a stable three-dimensional network without synthetic additives, allowing its semi-solid gels to remain in place for seven to fourteen days, the period most associated with adhesion formation. The gel forms a physical barrier that separates adjacent tissues while maintaining structural integrity throughout this period and then degrades without residue. Combined with approximately 22-fold enhanced viscosity, the technology represents a targeted biomaterial solution combining technological differentiation with proven clinical efficacy.

“Our materials are based on hyaluronic acid, a natural component of the extracellular matrix. They actively promote wound healing and tissue regeneration at the surgical site,” says Andong Chen, Overseas Business Manager at BioRegen.

The company’s impact lies in how its biomaterial science translates into clinical value. In specialties such as gynecology and ENT surgery, where adhesions can contribute to infertility, chronic pain or repeat interventions, prevention carries outsized importance. Rather than treating biomaterials as passive barriers, BioRegen positions them as healing platforms that both prevent unwanted tissue attachment and support tissue repair.

How does clinician collaboration support development and validation of regenerative surgical biomaterial technologies effectively?

What structural inefficiencies limit value extraction in today’s bioeconomy systems globally?

For decades, the bioeconomy has promised transformation. It has spoken the language of sustainability, circularity, and renewable resources, yet in practice it has remained constrained by linear thinking. Biological systems are grown, processed, and commercialized for a narrow set of outputs, while the majority of their molecular and functional complexity is sidelined. Biomass is funneled into a single primary product, even though it contains multiple co-products with distinct market value.

The consequence is not merely inefficiency but measurable economic loss. Industries built on biological resources routinely monetize only a fraction of the value embedded in what they cultivate, leaving substantial revenue unrealized. What appears to be resource utilization is, in financial terms, systematic value leakage.

How does S-Bridges address value leakage in biological resource processing systems today?

S-Bridges was founded to address this utilization gap through a model that integrates biological processing, data infrastructure, and industrial deployment structures. Emerging from Japan with a model that combines deep biological science, digital infrastructure, and industrial pragmatism, the company is building a biomaterial transformation platform designed to recover, quantify, and monetize the value of natural capital that is traditionally left unrealized.

Rather than treating biological complexity as waste or an externality, S-Bridges converts it into measurable and investable circular value. Its ambition is to make full-spectrum, use-it-all biomass utilization commercially viable at scale, embedding nature-positive outcomes directly into production decisions and turning value leakage into value creation.

“At the center of our ambition is a simple but radical premise. If nature is the most capital-intensive input in the global economy, then 100 percent of biological material must be treated as value, not residue,” says Takashi Nagato, CEO. This premise underpins a proprietary processing system the company calls Cell Breaker^®, designed to make full utilization technically and economically viable.

The Structural Blind Spot of Biomass Industries

Why do existing biomass processing systems fail to capture full material value today?

Across agriculture, food, and materials industries, plant biomass is routinely processed with significant inefficiency. Crops are cultivated using land, water, energy, and labor, yet only a fraction of the plant enters the value chain. Leaves, stems, pomace, and fibers that are rich in proteins, functional compounds, and chemical building blocks are treated as waste or relegated to low-value applications.

In many cases, this reflects legacy processing structures optimized for single outputs rather than integrated multistream recovery. Even advanced biorefineries often optimize for one dominant product, leaving the rest of the biomass structurally undervalued.

S-Bridges approaches the problem from the opposite direction. Instead of asking how to extract one valuable compound efficiently, it asks how to design a system in which every component of a plant is assigned its highest possible use economically, functionally, and environmentally.

Cell Breaker^® and the Logic of Full Utilization

How does Cell Breaker^® enable full-spectrum biomass utilization across different feedstocks effectively?

The physical foundation of S-Bridges’ platform is the Cell Breaker^® system, a proprietary wet-milling and fractionation technology engineered to unlock plant cell structures with precision rather than brute force. Unlike conventional processing methods that degrade biomass to reach a single target, Cell Breaker^® separates botanical materials into multiple intact streams, including proteins, fibers, sugars, chemical compounds, and biofertilizer inputs.

Developing a life-saving therapy is a journey marked by breakthroughs and bottlenecks. Among the most challenging steps is scaleup—when a process that thrives in a laboratory flask must perform flawlessly in a 2,000-liter bioreactor.

Variability can creep in, productivity may falter, and regulatory compliance becomes more complex. For biopharmaceutical developers, these challenges jeopardize timelines and delay the hope of treatments reaching patients.

Ajinomoto CELLiST Korea exists to eliminate those uncertainties.

“Our mission is to deliver more than just media. We deliver confidence that therapies can progress from concept to commercial production while maintaining uncompromised quality and reliability,” says Dr. Masakazu Sugiyama, president.

From its headquarters in Songdo, Incheon—one of Asia’s leading bio-clusters—Ajinomoto CELLiST Korea anchors its strategy on a clear identity.

Its mission is to contribute to medical advancement and better lives by providing cell culture media. Its vision is to become Asia’s most preferred and trusted cell culture media supplier. And its values are rooted in a customer-centered culture, operational excellence, and the promise of stable, speedy, and superb quality. This foundation ensures that every decision, from scientific innovation to customer partnership, aligns with long-term trust and reliability.

Bridging Asia and the Global Biopharmaceutical Market

What sets Ajinomoto CELLiST Korea apart is its dual positioning: deeply rooted in Asia while seamlessly connected to the global biopharmaceutical ecosystem. As part of the Ajinomoto Group—a company with a long history in biotechnology and amino acid science leadership—Ajinomoto CELLiST Korea leverages global expertise while tailoring solutions to regional growth trends.

Asia’s demand for advanced therapies is expanding rapidly. By supporting both multinational firms and regional champions, Ajinomoto CELLiST Korea acts as a strategic bridge, enabling the globalization of biopharmaceutical manufacturing and accelerating the path of therapies from Asia to the world.

Ajinomoto’s long-standing AminoScience heritage gives Ajinomoto CELLiST Korea a unique edge in designing highly optimized media formulations. This expertise extends beyond antibody manufacturing into next-generation modalities such as vaccines, cell therapies, and gene therapies. This breadth reflects not only scientific ingenuity but also a commitment to enabling the therapies of tomorrow. Each formulation is designed with scalability, sustainability, and regulatory readiness in mind.

Overcoming the Scale-Up Challenge

For many developers, the transition from research-scale to commercial-scale production introduces hurdles. A formulation that supports steady growth in the lab may falter under the stresses of large-scale bioreactors.

Ajinomoto CELLiST Korea addresses these challenges head-on. Its experts optimize media to support higher cell densities, longer cultures, and diverse bioreactor systems. They control impurities with advanced analytics; ensuring trace components do not compromise yield or quality.

By applying Ajinomoto Group’s biotechnology expertise, the company guarantees reproducibility across batches, enabling developers to move confidently from discovery to large-scale manufacturing.

Confidence through Quality and Compliance

Reliability in biopharmaceuticals is built on more than performance. It requires uncompromising adherence to quality and safety. Ajinomoto CELLiST Korea ensures this through rigorous GMP-like controls supported by comprehensive quality assurance and traceability systems.

Its scientific precision in formulation enables consistency and reproducibility from research to commercial scale. At the same time, the company invests steadily in process improvements and technological advancements, ensuring scalability and preparing for future biologics such as monoclonal antibodies and advanced modalities.

This three-pronged approach delivers confidence not only in today’s processes but also in the evolving needs of tomorrow.

In the race to develop safer, smarter, and more sustainable health solutions, one company has redefined what’s possible with chitosan.

BIO21, operating from a GMP, HACCP, FDA-approved, EU-certified facility in Indonesia in partnership with PT. Fresh On Time Seafood, controls every stage from ocean harvest to molecular-level formulation. This rare vertical integration, combined with advanced R&D expertise, has made the company a trusted partner for life science innovators across Europe, North America, and Japan.

Founded in 2005 and headquartered in Thailand, BIO21’s vertically integrated model is its greatest strength. From harvesting snow crab shells in deep-sea, low-pollution environments to delivering medical-grade chitosan, BIO21 controls every stage of the journey. Few suppliers can match its commitment to double raw material checks—first for seafood fit for human consumption, then again for suitability as a pharmaceutical-grade biopolymer.

The company’s approach ensures every batch meets the highest safety and purity standards. But BIO21’s competitive edge goes far beyond compliance. Its research and development team specializes in engineering chitosan at the molecular level.

Critical parameters such as degree of deacetylation, molecular weight, viscosity, and chitosan type (alpha or beta) are precisely tailored to meet the functional, clinical, and regulatory needs of each client. The capacity for fine-tuning is not common in the industry, and it has made BIO21 a trusted partner for high-stakes applications.

One example of BIO21’s problem-solving ability can be seen in its work with a medical device company developing a next-generation hemostatic dressing. The client needed biodegradable polymer materials that could pass rigorous EU and FDA standards. BIO21 responded with a custom formulation, carefully optimizing molecular weight, viscosity, and purity to meet exact specifications. Beyond supplying the material, the company actively supported the testing process and helped streamline regulatory documentation, leading to faster approval and a smoother product launch.

Treating Sustainability as a Core Design Principle

The company’s innovation pipeline is equally notable in the nutraceutical space. Its L112 Biopolymer, developed through close R&D collaboration, is designed to support cardiovascular health and fat reduction. Projects like this show how BIO21 transforms raw scientific expertise into real-world, market-ready performance.

Biomedical innovation across the Asia-Pacific (APAC) is moving through a period of practical transformation as healthcare systems place a stronger emphasis on material performance, biocompatibility, manufacturing precision, and treatment adaptability. Medical manufacturers, research institutions, and healthcare providers are investing more heavily in advanced material engineering because clinical outcomes increasingly depend on how medical materials behave inside complex biological environments. Demand is expanding across implants, regenerative medicine, wound care, surgical devices, drug delivery systems, and tissue engineering applications, where performance expectations continue rising.

Shifting Priorities across Biomaterial Innovation Ecosystems

Healthcare manufacturers across APAC are placing greater importance on customized biomaterial development as medical treatments become more specialized and patient-specific. Standardized material formulations no longer satisfy every clinical application, particularly in areas involving orthopedic reconstruction, cardiovascular intervention, dental restoration, and regenerative therapies.

Research teams are working more closely with clinicians to understand how biomaterials interact with living tissue under varied physiological conditions. Material selection now involves broader considerations involving flexibility, biodegradability, inflammatory response, and long-term integration with surrounding biological structures. Biomedical material product development has therefore become far more interdisciplinary than earlier manufacturing approaches that focused primarily on structural durability.

Regional healthcare expansion is also influencing material development priorities. Aging populations across several APAC economies are increasing demand for implants, rehabilitation devices, and minimally invasive treatment technologies that require highly reliable biomaterials. Surgical procedures involving joint repair, spinal intervention, and cardiovascular treatment rely heavily on materials capable of maintaining stability without creating adverse biological reactions over extended periods.

Material scientists are responding by refining polymer engineering, ceramic composites, and bioactive coatings that improve compatibility while reducing recovery complications. Clinical expectations surrounding comfort, longevity, and healing support are shaping how medical materials are designed from the earliest development stages.

Academic research partnerships are becoming more visible throughout the sector as universities, laboratories, and healthcare institutions collaborate more closely on translational biomaterial research. Scientific exploration involving nanomaterials, hydrogel systems, and tissue scaffolding technologies is increasingly moving toward commercial application rather than remaining confined to experimental settings.

Balancing Clinical Precision with Development Complexity

Material consistency remains one of the more technically demanding aspects of biomedical development across APAC healthcare manufacturing environments. Biomaterials often behave differently under changing biological conditions, making performance predictability essential for long-term clinical safety. Small variations in composition, sterilization exposure, or manufacturing temperature can influence how materials interact with tissue after implantation or therapeutic use.

Development teams are addressing that challenge through stricter validation systems, advanced simulation testing, and more controlled production monitoring that evaluates material behavior under multiple physiological conditions before commercial deployment. Clinical confidence improves when biomaterial performance can be measured more accurately across varied treatment environments.

Regulatory alignment also presents operational complexity because healthcare approval standards differ across APAC jurisdictions. Medical materials used within implantable devices, tissue applications, or drug delivery systems often require extensive biocompatibility testing and long-term safety documentation before entering broader healthcare markets.

Product developers are responding by integrating regulatory planning earlier within research and engineering workflows rather than treating compliance as a final-stage administrative process. Stronger coordination between material scientists, clinical researchers, and regulatory specialists helps reduce development delays while improving documentation quality throughout approval procedures.

Supply chain reliability has become increasingly important as advanced biomaterials often depend on specialized raw materials and highly controlled manufacturing inputs. Healthcare manufacturers operating across multiple countries can face difficulties maintaining uniform quality standards when sourcing materials from fragmented supplier networks.

Development organizations are improving supply consistency through regional sourcing partnerships, tighter material traceability systems, and expanded quality auditing throughout procurement channels. Production stability improves because material integrity can be monitored more effectively from raw sourcing through final product assembly.

Expanding Medical Possibilities through Advanced Material Engineering

Artificial intelligence is beginning to reshape biomaterial research by improving how scientists analyze molecular interactions, predict material behavior, and evaluate treatment compatibility across large biological datasets. Analytical systems can process research variables involving degradation rates, cellular response patterns, structural stability, and tissue integration far more efficiently than traditional manual evaluation methods. Development planning becomes more targeted because material candidates with lower clinical viability can be identified earlier, before extensive laboratory resources are committed to large-scale testing.

“Healthcare manufacturers across APAC are placing greater importance on customized biomaterial development as medical treatments become more specialized and patient-specific.”

Regenerative medicine is also creating broader opportunities throughout the APAC biomaterials sector. Tissue repair technologies, bioengineered scaffolds, and cellular regeneration therapies increasingly depend on highly specialized materials capable of supporting biological growth while gradually integrating with natural tissue structures. Healthcare providers are placing stronger emphasis on treatment approaches that encourage healing support rather than relying solely on permanent mechanical replacement. Material innovation is therefore moving closer toward biologically responsive systems that interact dynamically with human tissue during recovery and regeneration processes.

Nanotechnology applications are attracting significant attention within advanced medical material development. Nanostructured coatings, targeted drug delivery carriers, and antimicrobial surface technologies are improving how medical products perform under highly sensitive clinical conditions.

Smaller-scale material engineering allows developers to influence cellular interaction with greater precision, particularly in applications involving infection control, localized therapeutic delivery, and implant integration. Biomedical material product development is benefiting from nanotechnology because microscopic material modifications can create measurable improvements in patient safety and treatment performance.

Biomaterial transformation solutions are reshaping healthcare systems across APAC by aligning clinical innovation with environmental responsibility. The growing demand for advanced therapies and sustainable practices is driving a shift toward materials that not only perform biologically but also reduce ecological impact. Healthcare providers and life sciences companies are increasingly integrating biodegradable, renewable, and engineered biomaterials, creating a new balance between patient outcomes and sustainability goals.

Advancing Regenerative Medicine through Sustainable Design

Biomaterial innovation is accelerating the transition from conventional treatment models toward regenerative healthcare. Instead of relying on inert materials, modern solutions focus on bioactive and biodegradable structures that actively interact with the human body. These materials support tissue repair, enhance healing processes, and reduce the need for repeated interventions. The emergence of smart scaffolds and bioengineered matrices has significantly improved the restoration of damaged tissues, offering more natural and long-lasting recovery pathways.

A key development in the region is the adoption of decellularized extracellular matrices that mimic natural tissue environments. These materials enable better cell attachment and growth while minimizing immune response. Their application in wound care and orthopedic treatments is expanding rapidly, supported by scalable manufacturing capabilities that ensure consistency and quality. At the same time, 3D biofabrication techniques are enabling the creation of patient-specific implants and tissue constructs, reducing material waste and improving clinical precision.

This transformation is not limited to treatment outcomes. By using materials that degrade safely within the body, healthcare systems can reduce reliance on resource-intensive surgical procedures. The integration of regenerative biomaterials into clinical workflows is helping providers move toward therapies that heal rather than manage conditions, contributing to both environmental and economic sustainability.

Enabling Circular Bioeconomy and Green Manufacturing

Sustainability in healthcare is increasingly tied to how biomaterials are sourced, produced, and managed throughout their lifecycle. Transformation solutions are now focusing on circular models that minimize waste and maximize resource efficiency. By utilizing renewable feedstocks and biological processes, manufacturers are developing biomaterials that align with green production principles while maintaining high-performance standards.

Synthetic biology is playing a central role in this shift. Engineered microorganisms are being used to produce high-value biomaterials from organic inputs, including agricultural byproducts. This approach not only reduces dependency on traditional raw materials but also converts waste into valuable medical resources. The concept of carbon-conscious manufacturing is gaining traction as organizations adopt production methods that lower emissions and promote environmental balance.

Another important aspect is the management of biomaterial waste. As the use of implants, devices, and disposable medical products increases, so does the need for sustainable disposal and recycling strategies. Efforts are being made to improve the recyclability of biomaterials and to design products that can be safely reprocessed or biodegraded after use. Lifecycle assessments are becoming a critical tool in evaluating environmental impact and guiding innovation toward more sustainable outcomes.

The integration of digital technologies further enhances sustainability efforts. Data-driven manufacturing and automation enable precise control over material usage, reducing excess production and improving efficiency. These advancements are helping healthcare systems transition toward models that prioritize both performance and environmental stewardship.

Driving Innovation in Smart Therapeutics and Precision Care

Biomaterial transformation is also redefining how therapies are delivered and personalized. The convergence of materials science, nanotechnology, and data intelligence is enabling the development of smart therapeutic platforms. These platforms are designed to respond to biological signals, release drugs in a controlled manner, and adapt to patient-specific conditions.

Nanostructured biomaterials and responsive polymers are used to develop targeted drug delivery systems that enhance treatment efficacy while reducing side effects. Hydrogels, nanoparticles, and micro-scale delivery mechanisms are enabling precise dosing and localized therapy, minimizing systemic impact. These innovations are particularly valuable in managing complex conditions where traditional treatments may fall short.

Artificial intelligence is further accelerating the development of advanced biomaterials by enabling rapid material discovery and optimization. Machine learning models can predict how materials will behave in biological environments, allowing researchers to design solutions with greater accuracy and speed. This integration of digital intelligence is transforming biomaterials into programmable systems that can be tailored to individual patient needs.

The rise of bio-derived and three-dimensional materials is opening new possibilities for wound care and tissue regeneration. These materials can be engineered to release therapeutic agents gradually, supporting continuous healing and reducing the need for frequent interventions. Such approaches not only enhance patient experience but also contribute to resource efficiency within healthcare systems.

Biomaterial transformation solutions are ultimately creating a more adaptive and sustainable healthcare ecosystem across APAC. By combining regenerative science, circular production models, and intelligent therapeutic design, the region is advancing toward a future where medical innovation and environmental responsibility are closely aligned.

The cell culture medium, across the biotechnology of the Asia-Pacific (APAC) region, is evolving into an intelligent, highly engineered tool that dictates cellular fate and function with unprecedented precision. This shift is fueling breakthroughs in biomanufacturing, regenerative medicine, and drug discovery. The narrative is no longer just about keeping cells alive; it’s about instructing them to build, produce, and heal. This evolution is spearheaded by three interconnected frontiers: AI-driven predictive optimization, specialized formulations for complex 3D tissue models, and the emergence of media as a programmable substrate for next-generation applications.

AI-Driven Media Optimization: Predictive Modeling for Peak Performance

For decades, developing the perfect cell culture medium was a painstaking process of trial and error. Researchers would adjust dozens of components, a slow and resource-intensive approach. Today, innovators in the APAC region are leaving this empirical method behind, embracing the power of AI and predictive modeling to design media with surgical accuracy.

This new paradigm harnesses high-throughput screening systems that can test thousands of unique media formulations simultaneously. The vast datasets generated—encompassing cell growth rates, viability, and protein production—are fed into sophisticated machine learning algorithms. These algorithms analyze complex, non-linear interactions between media components that are impossible for humans to discern.

By integrating multi-omics data (genomics, proteomics, metabolomics), the models can understand a cell line's unique metabolic needs and genetic predispositions. This allows for the creation of truly bespoke media that can, for instance, maximize the yield of a specific monoclonal antibody from a CHO cell line or guide stem cells towards a desired lineage with higher fidelity. The result is a dramatic acceleration of development timelines for new biologics and cell therapies. This data-driven approach is transforming biomanufacturing in the region, leading to more consistent, potent, and cost-effective production processes.

3D Culture and Organoid Media Supporting Complex Architectures

The limitations of traditional 2D cell culture, where cells grow in a flat monolayer on plastic, are well-documented. These models fail to replicate the complex cell-to-cell and cell-to-matrix interactions found within living tissues. The APAC region's research powerhouses are at the forefront of adopting 3D culture systems and organoids—miniature, self-organizing organs grown in a dish—to create far more physiologically relevant models. The success of these advanced models hinges entirely on the sophistication of their culture media.

Media for organoids is far more than a simple nutrient source; it's an instructive microenvironment.³ These formulations are meticulously designed to provide the precise biochemical and physical cues that guide stem cells to differentiate and self-assemble into complex structures mimicking human organs like the gut, brain, or liver. They are enriched with a specific cocktail of growth factors, signaling molecules, and extracellular matrix (ECM) components that recapitulate the developmental processes of a real organ.

The impact of this is profound, particularly for drug screening and personalized medicine. By growing organoids derived from a patient's own cells, researchers can test the efficacy and toxicity of various drugs on a model that mirrors the patient's unique biology. This opens the door to developing tailored treatment strategies, predicting patient responses, and reducing reliance on animal testing. The specialized media enabling these intricate tissue models are a cornerstone of the next wave of medical innovation, allowing scientists to study disease and develop therapies with a new level of biological accuracy.

Media as a Programmable Substrate in Bioprinting and Synthetic Biology

Pushing the boundaries even further, the most advanced cell culture media are now being engineered as programmable substrates for a new generation of biotechnologies like bioprinting and synthetic biology. In this context, the medium transcends its role as a passive liquid and becomes an active, functional component of the final product.

In 3D bioprinting, the cell-laden media, often called bio-ink, must possess a unique combination of biological and rheological properties. It needs to be viscous enough to be printed into stable, intricate structures, but not so viscous that it harms the cells during the extrusion process. Once printed, the bio-ink's formulation must support cell viability, encourage tissue maturation, and eventually degrade as the cells produce their own native ECM. Researchers are designing these bio-inks to contain signaling molecules that can spatially guide cell differentiation within the printed construct, effectively programming the development of complex, multi-layered tissues.

Simultaneously, the field of synthetic biology is leveraging media to control genetically engineered cells. Scientists can design "smart" media containing specific inducer molecules that act as on/off switches for synthetic gene circuits. This allows for precise temporal control over cellular behavior. For example, a particular compound in the medium could trigger a population of engineered bacteria to begin producing a therapeutic protein or a valuable chemical. Here, the medium and the cell form a cohesive, programmable system. This collaboration is unlocking novel applications in everything from sustainable manufacturing and biosensing to the development of living therapeutics, with APAC's synbio ecosystem playing a pivotal role in this futuristic endeavor.

As these trends converge, the future of biotechnology is being written in the composition of cell culture media. From AI-optimized bioproduction to patient-specific organoids and printed tissues, the intelligent elixir flowing through the bioreactors and petri dishes of the APAC region is not just sustaining life—it's actively programming it.

Leadership is a fundamental skill required in all areas and sections within healthcare organisations. The leadership of the team seems simple and although it is a combination of multiple disciplines / skills / roles; it actually is!

One philosophy of team leadership in my view is one of best outcome for patients / clients, through each component of the team working together hand in hand with each other.

The ‘team’ is the object – each member and role is equally important in the process / function of the delivery of best care.  It is not about treating one discipline more or less important within the group.  The philosophy is a holistic one that facilitates the organisations strategies to improve the patient / client journey, i.e. improved access, appropriate service and good outcomes.  This leads to more care benefits, added value, user feedback and more strategic thinking and planning.

Each discipline of the team has different needs / skills required to complete the workflows.  These have to be considered independently and in discussion, with those groups involved.  This is carried out through routine stakeholder and group review that includes process detail examination.  However, as part of this discussion, the group benefits from the integrated understanding, required as part of functioning together.  The integration will be addressed, discussed, strategised, solution driven, agreed and tested for implementation.

Through this process above, the outcomes are accepted more easily with modified services and workflows.  It is more complicated and time consuming, as necessary, with reviews for full change management, modification or totally new methods / models of care.

I would draw you back to the team and the single philosophy of providing best care.  The drive is not the individual or the discipline but the integrated workflow each group portrays in the overall service.  The combination of their skills and understanding of the workflow, bond the service together for the expected outcome.

Not all the workflows are even, not everyone is paid the same, or works the same hours / days, however, as repetitive as some may think, the goal, is the common based outcome for everyone.  Even though, from an organisational view, Medical Imaging (MI) is only one component of the patients / clients journey through the organisation.

[QUOTE1_Replace] 

Leadership from a team’s perspective can be seen as difficult, as all teams have many needs, opinions, agenda’s, history, like and dislikes, expectations, collateral impact, external stakeholders, just to name a few.  All these aspects need addressing and are important to be heard, but have to be drawn back and gravitated to ‘again’ the one goal and that is for the MI team to work together to generate the best outcomes.  We as a MI team have to enable and allow through the strategy process: innovation, ideas and individual feedback to be part of the routine practice, aligned with that of the organisation.

All discussions undertaken have to take into consideration the unique circumstances that may be presented and the impact they have, however, any final decisions have to be aligned with the expected outcomes and what the impact of these, will have upon it.

Rightly or wrongly you have to be aware of the individuals and align the disciplines within them, as a single team and have a simple common organisational strategic goal, which assists them in producing the right, expected outcomes for those requiring and using the service to be provided.

Asia-Pacific is the largest and most diverse region in the world, with multiple healthcare systems and specific regulations, whichrequires a deep understanding of the main challenges to better navigate this unique ecosystem.

If we look at the healthcare infrastructure andthe medical servicesaccessin APAC,we can observea wide varietyamong the different countries. Some countries may have a well-developed healthcare system, while others may face serious resource constraints. Despite these differences, there is one point in common within the region, which is the fact that life expectancy is increasing, which requires that patients have access to better treatments. To guarantee access to innovative treatments is a challenge for many countriesworldwide but is especially important for this part of the world which accounts for more than half of the global population.

How to deploy the best drug development strategy for APAC?

By understanding the local healthcare environment, being able to definestrategies that are tailored to the region’s needs, and dealing with each country’s individual challenges. It is important to payspecial attention to the countries that require ethnic differences to be addressed early in advance or to the ones that require apercentage of their population to be represented in the development.As the region is home to diverse ethnicitiesand genetic profiles, it is important to consider these specificities, ensuring that the different populations are represented within the trial.

[QUOTE1_Replace]

It is also important toengage key local stakeholders, including investigators, opinion leaders, patient advocacy groups, and regulatory authoritiesadaptingit to the local context as it can support you to better navigate the regional landscape and to gain the necessary support for successful trial implementation.

What are the main challenges to conducting clinical trials in APAC?

The fact that there is not a common regulatory framework, sometimes even differences in the disease epidemiology or medical practicemay be observed, leading to the need to adapt the strategy according to the specific country you are targeting within the region. It is not advisable to rely solely on a one-size-fits-all approach when transitioning from one country to another.Patient recruitment and retention, for example, may be impacted bycultural beliefs, attitudes, and practices related to healthcare and clinical research, and one example is the use of traditional medicine, whichiscommonly used in many Asian countries, which may impact the trial.

Rose Fida, Executive Director and Regional Lead of R&D for Japan & China at CSL, is an innovative leader with extensive experience in drug development, R&D governance, and strategic project management. With a steadfast commitment to advancing treatments for unmet medical needs, Rose drives impactful research programs across the Asia-Pacific region, driving innnovation to improve patient outcomes.

In an exclusive interview with Life Sciences Review APAC, Rose shares her perspective regarding the industry, sharing valuable insights into current developments, emerging challenges, and the future of therapeutic innovation.

1. Can you share your professional journey and the experiences that led you to your current role at CSL?

Growing up, I had a natural aptitude for mathematics and a passion for science and medicine. Despite winning a university-level maths competition at 15, a teacher advised me not to pursue science or maths, saying these weren’t “careers for girls.” That moment became defining—it fuelled my determination to prove that gender should never limit ambition. Fortunately, my parents encouraged me to pursue a biomedical career.

After my Honours degree, I earned a PhD in Physiology, focusing on serotonin in colonic motility. I then joined the Victorian College of Pharmacy as a Senior Scientist, working in pharmacokinetics—a field I initially knew little about. With supportive colleagues, I learned that success depends not on entering industry with a complete skill set, but on a willingness to learn. After 18 months, I became Pharmacokinetics Team Leader, sparking my enduring interest in drug development.

A personal turning point came when my father was diagnosed with cancer, which shifted my career to oncology drug development. At Mayne Pharma, I became Global Project Leader within 2.5 years, despite having no initial project management experience. Later, at Cytopia, I gained broad exposure to clinical, regulatory, and research domains. One of my proudest achievements was contributing to momelotinib, a treatment for myelofibrosis—later directly relevant to a family member.

[QUOTE1_Replace]

When Cytopia was acquired, I joined CSL, where I have held roles from Early Development to R&D Governance. Today, I serve as Regional Lead for R&D in Japan and China, based in Tokyo. Relocating without prior cultural immersion required courage but has been deeply enriching.

This global role allows me to align regional execution with global priorities while embracing cross-cultural leadership. Above all, my purpose remains clear: to contribute to therapies that improve lives.

2. What differentiates your leadership style when navigating regulatory, cultural, and operational differences across APAC markets?

Leading R&D across APAC markets demands more than operational oversight—it requires cultural fluency, regulatory agility, and a deep respect for local nuance. My leadership style is anchored in authenticity and adaptability. I prioritise building high-performing, cross-functional teams that are empowered to navigate complexity while staying aligned with global objectives. I focus on fostering cohesion without compromising local agility.

Leading R&D across the APAC region requires more than technical expertise and operational oversight — it requires cultural intelligence, regulatory agility, and a deep respect for local nuances. My leadership style is grounded in authenticity, adaptability, strategic clarity, and collaborative execution. I prioritise building high-performing, cross-functional teams that are empowered to navigate complexity while staying aligned with global objectives. I’ve contributed to the integration of Japan R&D into CSL’s global R&D operating model and framework, while supporting China R&D’s expansion through tailored operational models.

I believe in empowering regional teams to innovate within strategic guardrails. This means fostering a leadership culture that values both precision and agility. I focus on fostering cohesion without compromising local agility. By aligning talent strategy with portfolio needs, we ensure that our teams are not only compliant but also resilient and future-ready.

3. Pharmacokinetics (PK) data plays a critical role in shaping clinical development programs. How do you see CRO partnerships influencing the quality, speed, and reliability of these insights?

Pharmacokinetics (PK) data is the compass that guides clinical development. It informs dose selection, safety margins, and therapeutic windows. In today’s accelerated landscape, CRO partnerships are instrumental in ensuring that PK insights are not only scientifically robust but also operationally scalable. At CSL, we engage CROs early in the development cycle which enhances data quality, compresses timelines, and mitigates risk. At CSL, we view CROs as strategic collaborators, not just service providers.

The best CROs act as strategic extensions of our internal teams. They bring specialised capabilities in bioanalytical method development, population PK modelling, and adaptive trial design. Their ability to manage complex logistics across geographies—while maintaining data fidelity—is critical to our success.

4. CROs often face variability in patient demographics, trial site capacity, and regulatory expectations. What practices have proven most effective for you in managing these complexities?

CROs often operate in environments marked by demographic diversity, site variability, and shifting regulatory expectations. To manage this, we emphasise proactive planning, scenario modelling, and continuous communication that combines standardised frameworks with local flexibility. These practices not only reduce variability but also build trust and transparency across the partnership.

One effective practice has been embedding regional site managers within our regional teams to manage the local CROs. This fosters accountability, accelerates decision-making, and ensures that trial execution remains aligned with strategic goals. It also builds trust—an intangible but vital asset in global R&D.

5. What strategies do you use to keep regional PK and CRO operations aligned with global R&D priorities while preserving agility in local execution?

Maintaining alignment between regional PK operations and global R&D priorities is a balancing act. I advocate a dual-track approach: embedding global strategy into regional execution while preserving the autonomy and agility needed for local responsiveness. This involves regular cross-regional governance forums, shared KPIs, transparent communication, and a culture of mutual accountability. It also means empowering regional teams to innovate within guardrails—ensuring that local insights inform global decisions.

6. What’s one piece of advice you’d offer to emerging R&D leaders managing multi-country pharmacokinetics programs?

For those stepping into multi-country PK leadership roles, my advice is simple: lead with clarity, curiosity and courage.

Ambiguity is the enemy of alignment. Clarity in purpose, roles, and expectations fosters alignment.

Innovation often comes from unexpected places. Curiosity drives innovation and empathy—two qualities essential for navigating diverse teams and complex ecosystems. Stay open to new ideas, technologies, and cultural perspectives.

Be courageous - make bold decisions grounded in data and empathy. The path to transformative therapies is rarely linear.

Invest in relationships, embrace ambiguity, and remember that every data point represents a patient. Let that guide your decisions, inspire your teams, and shape your legacy.

When one thinks about recent innovations and hot topics in clinical development, big-ticket items like AI, technology, data science, and analytics come to mind. Advancements in each of these fields are now being more widely used and finally making a positive impact on bringing new drugs to market more efficiently. Other ‘hot’ areas include data privacy, health equity, clinical trial diversity and the need to manage R&D’s impact on the greenhouse effect. All in all, these elements make this one of the most interesting times to work in clinical development.

However, when I get asked by teams to support projects, I find myself time and again coming back to more basic strategies that involve the culture and behaviors of such teams – especially when it comes to challenging the status quo and acting with a sense of urgency. These are not often discussed as they are somewhat opaque and fuzzy in an industry that prizes things in black and white, standard operating procedures, governance and formality. Until humans are replaced by the technologies I alluded to at the start of this piece, we will always need to manage culture and relationships. If managed well, they drive performance.

I will share two small actions in a little more detail to illustrate what I mean. I was recently asked to support a project team charged with accelerating a clinical trial expanding into Asia Pacific. Upon assessing the situation, we identified several target areas to focus on. Firstly, we noticed that it sometimes took more than a month to schedule site initiation visits after all the other formalities were completed. When the usual approach didn’t work, the team didn’t waste time before asking the customer’s medical director to make contact, given their scientific seniority. Amazingly, one of these visits was brought forward by a whole month.

Another obstacle we identified was the long time translations were taking–a key step for document preparation in Asia. We discovered the source of the problem was the customer's preferred translation vendor. Rather than just accept this, we requested a change to our preferred translation vendor, with whom we had a long working relationship and established processes in place. In return, we gained a 50 percent decrease in translation times.

In both cases, by not accepting the status quo and demonstrating urgency, the team used rather simple, low-tech interventions to make significant improvements in how quickly we were able to start this study.

[QUOTE1_Replace]

Simple interventions like these become easier when strong relationships are built between teams, vendors, investigators and site staff, often outside of a project delivery setting. Clinical research associates (CRAs), for example, can draw upon the relationships built during face-to-face investigator engagements when encouraging site staff to push a little bit harder to enroll participants in a clinical trial. The beneficial effects are enhanced when a CRA has a long-standing and positive relationship with site staff, built over many interactions over many clinical trials. However, building relationships might come more naturally to some than to others. A CRA might purposefully keep note of the study coordinator's life events so that on their next monitoring visit, they can ask, "How was your daughter's first soccer game?" I want to be clear that the benefit does not merely lie with collecting relationships akin to friendships but in being able to leverage those relationships to enhance quality delivery on a clinical trial. So, the followup question after “How was your daughter's soccer game?" could be "How are we going with finding new patients for the study?” or “How are those data queries going?

It is hard to scale and measure this type of activity in an industry where everything is so data-driven. However, imagine if all of our teams were able to take such actions independently, including proactive negotiating and compressing timelines in responsible ways, how this would sustainably enhance management of a large portfolio of projects.

Today, I gave an example of the speed of site activation, as it is one of the metrics that are most often looked at and remains tremendously complicated. AI, data, and analytics are helping in so many aspects of this complex process, from translating documents, tracking progress, workflow management, and highlighting risk. But at the end of the day, you still need a human being to go to a site to perform an SIV, which involves interpersonal communications skills – and oftentimes, creative problem-solving -- to schedule a visit when all stakeholders at the site can be present. These behaviors and tactics also apply to patient recruitment, answering queries for a database lock, pumping out a clinical study report, and a myriad of other important deliverables in a project.

It is not possible in such a short piece to discuss in depth project team and corporate culture and dynamics, but I hope in this simple but frequently encountered example, you will see why I am repeatedly humbled by how something as simple as a picking up a phone and having a coffee with someone can solve a problem or spark a creative solution, out from under technology’s shadow. This ‘human dimension’ to the work of getting medicines to patients faster deserves more attention from leadership.